Dyne Therapeutics, Inc
DYN
NASDAQ
Biotechnology
$25.70
USD
-0.26 (-1.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.85B
Volume 1.7M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-519.40M
TTM
-25.8%
YoY
Operating Cash Flow
$-477.82M
TTM
-32.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 16.6 | 16.7 | 20.7 | 24.4 | 29.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 115.8 | 113.9 | 116.1 | 125.3 | 181.7 |
Operating Income | -115.8 | -113.9 | -116.1 | -125.3 | -181.7 |
EBITDA | -115.3 | -113.4 | -115.6 | -124.7 | -181.1 |
Other Income / Expense | -1.6 | 0.3 | -0.3 | -0.1 | -0.1 |
Total Other Income / Expense | 4.9 | 5.9 | 4.2 | 4.4 | 3.1 |
Income Before Income Taxes | -110.9 | -108.0 | -112.0 | -120.9 | -178.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -110.9 | -108.0 | -112.0 | -120.9 | -178.6 |
Consolidated Net Income / Loss | -110.9 | -108.0 | -112.0 | -120.9 | -178.6 |
Net Income Attributable to Common Shareholders | -110.9 | -108.0 | -112.0 | -120.9 | -178.6 |
Basic EPS | -$0.97 | -$0.76 | -$0.76 | -$0.73 | -$1.08 |
Diluted EPS | -$0.97 | -$0.76 | -$0.76 | -$0.73 | -$1.08 |
Basic Shares Outstanding | 113.9M | 141.8M | 148.2M | 165.0M | 165.5M |
Diluted Shares Outstanding | 113.9M | 141.8M | 148.2M | 165.0M | 165.5M |